Straits Times Index
3,187.05 +32.36 (+1.03%) Nikkei
38,090.87 +129.07 (+0.34%) Hang Seng
16,481.24 +229.40 (+1.41%) FTSE 100
7,847.99 +27.63 (+0.35%) Bitcoin USD
61,645.77 -2,229.41 (-3.49%) CMC Crypto 200
885.54 0.00 (0.00%)
Certara, Inc. (CERT)
After hours:
| Previous close | 17.07 |
| Open | 17.18 |
| Bid | 16.93 x 100 |
| Ask | 17.02 x 100 |
| Day's range | 16.94 - 17.34 |
| 52-week range | 11.81 - 24.96 |
| Volume | |
| Avg. volume | 552,969 |
| Market cap | 2.715B |
| Beta (5Y monthly) | 1.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.35 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 19.72 |
GlobeNewswireCertara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform
PRINCETON, N.J., April 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara Cloud, the unifying platform that integrates its many scientific software solutions. Customers log into Certara Cloud using a single ID to access and manage their licensed software, linking predictive solutions to modeling and analysis of clinical trial results. "This reusable suite of shared platform services enables us to bo
- GlobeNewswire
Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference
PRINCETON, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2024 after the market close on Tuesday, May 7th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. Certara al
GuruFocus.comInsider Sell: President of Drug Dev Solutions at Certara Inc (CERT) Sells Shares
Certara Inc (NASDAQ:CERT), a global leader in biosimulation, provides software, consulting, and technology-enabled services to support drug discovery, development, and regulatory science.
